Clinical trial
A 24-month Real Life PErsistence Efficacy and Safety Study in IBD Patients in REMission Switched From Intravenous Infliximab to Subcutaneous Infliximab CT-P13 Remsima®SC
NCT04990258 is registered in ClinicalTrials.gov with Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A 24-month Real Life PErsistence Efficacy and Safety Study in IBD Patients in REMission Switched From Intravenous Infliximab to Subcutaneous Infliximab CT-P13 Remsima®SC
- Lead sponsor
- Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- September 6, 2021
- Completion date
- September 30, 2024
- Enrollment
- 444 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.